PSA reactivity in extracellular microvesicles to commercial immunoassays

Sandúa, Amaia; Sanmamed, Miguel F.; Rodríguez, M. Fernández; Ancizu-Marckert, Javier; Gúrpide, Alfonso; Pérez-Gracia, José Luis; Alegre, Estíbaliz; González, Álvaro

doi:10.1016/j.cca.2023.117303

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The critical factor that determines the efficacy of early cancer detection is the analytical platform that converts invisible molecular binding events into optical or electrical signals ( Figure 1 ). The common methods used for the detection of cancer-specific antigens (biomarkers) include ELISA, and different types of immunosensor devices [ 16 , 48 , 101 , 102 ]. To date, most analytical platforms for the detection of cancer biomarkers use mAb as a sensing probe [ 10 , 14 , 20 , 68 , 70 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 ].…”

Section: Development Of Phage-driven Biosensors For the Detection Of ...mentioning

confidence: 99%

Phage Display’s Prospects for Early Diagnosis of Prostate Cancer

Petrenko

2024

Viruses

View full text Add to dashboard Cite

Prostate cancer (PC) is the second most diagnosed cancer among men. It was observed that early diagnosis of disease is highly beneficial for the survival of cancer patients. Therefore, the extension and increasing quality of life of PC patients can be achieved by broadening the cancer screening programs that are aimed at the identification of cancer manifestation in patients at earlier stages, before they demonstrate well-understood signs of the disease. Therefore, there is an urgent need for standard, sensitive, robust, and commonly available screening and diagnosis tools for the identification of early signs of cancer pathologies. In this respect, the “Holy Grail” of cancer researchers and bioengineers for decades has been molecular sensing probes that would allow for the diagnosis, prognosis, and monitoring of cancer diseases via their interaction with cell-secreted and cell-associated PC biomarkers, e.g., PSA and PSMA, respectively. At present, most PSA tests are performed at centralized laboratories using high-throughput total PSA immune analyzers, which are suitable for dedicated laboratories and are not readily available for broad health screenings. Therefore, the current trend in the detection of PC is the development of portable biosensors for mobile laboratories and individual use. Phage display, since its conception by George Smith in 1985, has emerged as a premier tool in molecular biology with widespread application. This review describes the role of the molecular evolution and phage display paradigm in revolutionizing the methods for the early diagnosis and monitoring of PC.

show abstract